Article details
Saudi Arabia’s Capital Market Authority (CMA) has approved Dallah Healthcare’s 20% capital increase, raising its total capital from SAR 1.02 billion to SAR 1.22 billion. The expansion will be executed through a 1-for-5 bonus share distribution, funded by SAR 109.53 million from the share premium account and SAR 93.61 million from statutory reserves. The company will issue 20.31 million new shares, increasing the total shares from 101.57 million to 121.89 million. The CMA emphasized that the company must hold an extraordinary general meeting within six months and complete all regulatory procedures.
This move strengthens Dallah Healthcare’s financial position by aligning its capital with total assets, potentially improving investor confidence. For traders, the bonus issue may temporarily dilute earnings per share but could enhance liquidity and market visibility. The approval also signals regulatory compliance, which is critical for maintaining the company’s listing status on Tadawul.
Saudi equity investors should monitor the timing of the extraordinary general meeting and the share distribution date. The capital increase may influence short-term stock volatility, especially if market sentiment reacts positively to the company’s financial restructuring. Traders should also assess how this move impacts Dallah Healthcare’s competitive positioning in the healthcare sector.
